Table 3 Univariate and multivariate analyses of baseline variables for 30-day mortality prediction in the training cohort

Male

2.2 (0.84–5.80)

0.11

Age

1 (0.97–1.10)

0.72

High obstruction

2.5 (0.99–6.30)

0.052

Two-stent placements

0.87 (0.11–7.10)

0.9

Lymph node metastasis

3.1 (1.2–7.9)

0.016

2.29 (0.59–8,98)

0.233

Distant metastasis

4.9 (1.9–12.0)

 < 0.001

7.96 (1.44–44.10)

0.018

Cholangitis before stent insertion

0.93 (0.3–2.9)

0.9

Post-ERCP complications

4.8 (2–12)

 < 0.001

6.03 (1.52–24.01)

0.011

Child–Pugh class C

3.3 (1.1–10.0)

0.032

1.14 (0.16–8.11)

0.894

Pancreatic Cancer

1

Gallbladder cancer

2 (0.49–8.10)

0.33

0.33 (0.03–3.40)

0.349

Cholangiocarcinoma

1.7 (0.6–5.0)

0.31

0.60 (0.13–2.71)

0.504

Ampullary cancer

0.6 (0.072–5.100)

0.64

1.06 (0.09–12.88)

0.966

Other

5 (1.3–19.0)

0.019

0.79 (0.10–5.99)

0.822

Ascites

2.6 (1.1–6.3)

0.029

1.25 (0.34–4.55)

0.738

White blood cell count (10⁹/L)

1.1 (1.0–1.2)

0.027

1.04 (0.93–1.16)

0.529

Red blood cell count (10¹²/L)

0.55 (0.27–1.10)

0.099

Hemoglobin (g/L)

0.98 (0.95–1.00)

0.089

Platelet (10⁹/L)

1 (0.99–1.00)

0.35

TB (mg/dl)

1 (1–1)

 < 0.001

1.01 (1.00–1.01)

0.009

ALT (u/L)

0.99 (0.98–1.00)

0.049

1.00 (0.99–1.01)

0.661

AST (u/L)

1 (0.99–1.00)

0.87

Albumin (g/L)

0.88 (0.81–0.96)

0.004

0.90 (0.78–1.03)

0.131

Creatinine (μmoI/L)

1 (1–1)

0.15

PT (s)

1.2 (1.0–1.4)

0.044

1.04 (0.87–1.24)

0.676

Successful drainage^a

0.11 (0.032–0.380)

 < 0.001

0.12 (0.03–0.54)

0.005